PAS funded by this sponsor. EU PAS ID Status RMP requirementTitle Protocol uploaded Results uploaded 3614 Finalised EU RMP category 3 Incidence of Pancreatic Malignancy and Thyroid Neoplasm in Type 2 Diabetes Mellitus Patients who Initiate Exenatide Compared to Other... Yes No 4577 Finalised Unspecified Physician Survey to Reassess Effectiveness of Strattera Risk Minimisation Activities Yes Yes 4894 Finalised Unspecified The Risk of Venous Thrombotic Events among Males Treated with Testosterone Replacement Therapy (I5E-MC-B003) Yes No 5599 Finalised EU RMP category 3 AN OBSERVATIONAL POST-AUTHORIZATION MODIFIED PRESCRIPTION-EVENT MONITORING SAFETY STUDY TO MONITOR THE SAFETY AND UTILIZATION OF EXENATIDE ONCE WEEKLY... Yes Yes 5911 Finalised EU RMP category 3 Prasugrel Treatment Patterns in Outpatient Settings in Germany, the United Kingdom, and France (H7T-MC-B011) No Yes 5924 Finalised EU RMP category 3 Treatment Patterns and Bleeding Risks Comparison in Patients Treated with Clopidogrel and Prasugrel during the Index Hospitalisation in Germany... No Yes 5934 Finalised EU RMP category 3 Treatment Patterns and Bleeding Risks Comparison in Patients Treated with Clopidogrel or Prasugrel during the Index Hospitalisation in Sweden... No Yes 5972 Finalised EU RMP category 3 Treatment patterns in acute myocardial infarction patients initiated with prasugrel or clopidogrel during the index hospitalisation with one year... No Yes 6305 Finalised EU RMP category 3 Strattera patient exposures and adherence in the United Kingdom, Germany, the Netherlands, and Sweden: 2014 Bi-annual assessment report Yes Yes 6355 Finalised EU RMP category 3 Assessment of the effectiveness of risk minimisation measures set up for new safety information for Efient® (Prasugrel): a multinational survey among... Yes No 6486 Finalised EU RMP category 3 Physician Survey to Assess Effectiveness of Strattera Risk Minimisation Activities in Prescribers Treating Adult Patients with ADHD Yes Yes 6736 Finalised EU RMP category 3 European Drug Usage Survey for Amyvid (I6E-MC-AVBF) Yes Yes 7584 Finalised EU RMP category 3 Hepatic Outcomes Among Adults Taking Duloxetine in a US Health Care Claims Database (F1J-MC-B037) No Yes 7588 Finalised EU RMP category 3 An Observational Study of Upper Gastrointestinal Tract (UGIT) Bleeding Events in Patients Taking Duloxetine and NSAIDs (F1J-MC-B040) No Yes 8540 Finalised EU RMP category 3 Forteo/Forsteo post-approval osteosarcoma surveillance study No Yes 8687 Finalised Unspecified Clinical and Economic Assessment of Patients with Acute Coronary Syndrome Managed with Percutaneous Coronary Intervention and Treated with Prasugrel... Yes Yes 9151 Finalised Unspecified Testosterone Replacement Therapy (TRT) and Risk of Acute Myocardial Infarction (AMI): An Administrative Healthcare Claims Study (F1D-MC-B006) Yes Yes 9318 Finalised Not included in RMP Safety Profile of Pemetrexed+Carboplatin AUC5 and Pemetrexed+Carboplatin AUC6 for Patients with Non-Small Cell Lung Cancer (H3E-MC-B025) Yes Yes 9400 Finalised EU RMP category 3 Safety and Effectiveness of Ramucirumab in Patients with Advanced Gastric Cancer in the European Union and North America: A Prospective Observational... Yes Yes 9938 Finalised Unspecified Comparison Of Clinical Outcomes, Resource Utilisation, And Costs In Patients Hospitalized For ACS Managed With PCI And Receiving Prasugrel Or... Yes No 9949 Finalised Unspecified Post-discharge Clinical and Economic Outcomes Among Patients with ACS Managed with PCI and treated with Prasugrel versus Ticagrelor (H7T-MC-B023) Yes No 10688 Finalised Not included in RMP Comparing Common Safety Outcomes in Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients Treated with Various First-line... Yes Yes 10786 Finalised EU RMP category 3 Strattera patient exposures and adherence in the United Kingdom, Germany, the Netherlands, and Sweden: 2016 Bi-annual assessment report. (B4Z-MC-B025) Yes Yes 11221 Finalised Non-EU RMP-only The Risk of Dystonia among Children and Adolescents Treated with Atomoxetine within the Truven MarketScan Database (B4Z-MC-B031) Yes Yes 11867 Ongoing EU RMP category 3 Evaluation of Effectiveness of Amyvid Reader Training (I6E-AV-AVBE) Yes No 12592 Finalised EU RMP category 3 Post-injection Syndrome in Patients with Schizophrenia Receiving Olanzapine Long-Acting Injection (F1D-MC-B034) Yes Yes 12595 Ongoing EU RMP category 3 Prospective International Observational Cohort Study Assessing Safety Outcomes Among Squamous Non-small Cell Lung Cancer Patients Treated with... Yes No 13266 Finalised EU RMP category 3 Observational Study Description H6D-MC-LVHQ(b) A Prospective Case-Crossover Study to Evaluate the Possible Association Between the Use of PDE5... No Yes 13422 Finalised EU RMP category 3 Healthcare Professional and Patient Surveys to Assess the Effectiveness of Risk Minimisation Measures for Concentrated Insulin Lispro (Humalog 200... Yes Yes 13783 Finalised EU RMP category 3 Utilisation of dulaglutide in European countries: A cross-sectional, multi-country and multi-source drug utilisation study using electronic health... Yes Yes 14445 Finalised EU RMP category 3 Dulaglutide Modified-Prescription-Event Monitoring Study and network database study: a multi-database collaborative research program of observational... Yes Yes 14789 Ongoing Non-EU RMP-only Healthcare Professional and Patient Surveys to Assess the Effectiveness of Risk Minimization Measures for Concentrated Insulin Lispro (Humalog 200... Yes No 14792 Finalised Non-EU RMP-only Healthcare Professional Survey to Assess the Effectiveness of Risk Evaluation and Mitigation Strategy for Dulaglutide (H9X-MC-B002) Yes No 15481 Planned EU RMP category 3 Observational Study to Assess Maternal and Fetal Outcomes Following Exposure to Ixekizumab (I1F-MC-B005) Yes No 15717 Finalised Not included in RMP The Genetics and Neuroendocrinology of Short Stature International Study (GeNeSIS) (GeNeSIS B9R-EW-GDFC) No Yes 15946 Finalised EU RMP category 3 Observational Studies to Assess Maternal and Fetal Outcomes Following Exposure to Duloxetine (F1J-MC-B057) Yes Yes 17371 Finalised EU RMP category 3 Strattera patient exposures and adherence in the United Kingdom, Germany, the Netherlands, and Sweden: 2018 Bi-annual assessment report (B4Z-MC-B026) Yes Yes 18117 Finalised Not included in RMP Assessing the Incidence of Osteosarcoma Among Teriparatide Users Using Medicare Part D and State Cancer Registry Data (B3D-MC-GHBX Addendum 2.2) Yes Yes 18132 Ongoing EU RMP category 3 A Prospective, Observational Study to Assess the Long-Term Safety of Ixekizumab Compared with Other Therapies Used in the Treatment of Adults with... Yes No 18547 Finalised Not included in RMP Observational study assessing incidence of osteosarcoma among Forteo(teriparatide) users by linking state cancer registry data to large national... Yes Yes 20159 Ongoing Non-EU RMP-only Healthcare Professional Survey to Assess the Effectiveness of Risk Evaluation and Mitigation Strategy for Dulaglutide (36 Month) (H9X-MC-B003) Yes No 20247 Finalised EU RMP category 3 Stress Urinary Incontinence and Suicidality Seen in the United Kingdom General Practice Research Database (F1J-MC-B056) No Yes 20253 Finalised Non-EU RMP-only Observational Study to Assess Maternal and Fetal Outcomes Following Exposure to Duloxetine (F1J-MC-B059) Yes No 21539 Planned Non-EU RMP-only Healthcare Professional Survey to Assess the Effectiveness of Additional Risk Minimization Measures for Prescribing and Administration of Concentrated... Yes No 21548 Ongoing Not included in RMP Real world glycemic effectiveness of linagliptin (Tradjenta®) among type 2 diabetes mellitus adults by age and renal function. No No 23516 Planned Non-EU RMP-only Healthcare Professional Survey to Assess the Effectiveness of Additional Risk Minimization Measures for Prescribing and Administration of Concentrated... Yes No 24207 Ongoing Not included in RMP Psoriasis Study of Health Outcomes – an International Observational Study of 3 Year Health Outcomes in the Biologic Treatment of Moderate to Severe... No No 24371 Ongoing EU RMP category 3 Assessment of off-label use of baricitinib in the paediatric population (Paediatric use of baricitinib) No No 25142 Ongoing EU RMP category 3 Post Marketing Safety Surveillance of Baricitinib in Three European Registries (I4V-MC-B012) Yes No 25151 Ongoing EU RMP category 3 A Retrospective Cohort Study to Assess the Safety of Baricitinib Compared with Other Therapies Used in the Treatment of Rheumatoid Arthritis in Nordic... No Yes 25154 Finalised EU RMP category 3 Rheumatologist Survey to Assess the Effectiveness of the Risk Minimisation Measures (RMM) for Olumiant® (baricitinib) a JAK1/2 inhibitor (I4V-MC-B010) Yes Yes 25164 Planned Not included in RMP A Multinational, Prospective, Observational Study of the Effectiveness, Healthcare Resource Utilization and Costs in Patients with Rheumatoid... No No 27574 Ongoing EU RMP category 3 Observational Cohort Study of Exposure to Galcanezumab during Pregnancy (I5Q-MC-B003) Yes No 27594 Ongoing EU RMP category 3 A Retrospective Cohort Study to Assess Drug Utilisation and Long-Term Safety of Galcanezumab in European Patients in the Course of Routine Clinical... Yes No 27597 Ongoing EU RMP category 3 A Retrospective Cohort Study to Assess Drug Utilisation and Long-Term Safety of Galcanezumab in US Patients in the Course of Routine Clinical Care... Yes No 28151 Ongoing Non-EU RMP-only Prospective pregnancy study to assess maternal and fetal outcomes following exposure to galcanezumab (I5Q-MC-B005) Yes No 31111 Ongoing Not included in RMP Risk Factors Associated with Severe Hypoglycemia Among Patients with Type 2 Diabetes Mellitus Treated with Insulin (Risk factors for severe... Yes No 31174 Planned Not included in RMP Psoriatic Arthritis Observational Study of Persistence of Treatment (PRO-SPIRIT Study) No No 32169 Finalised Not included in RMP Treatment Patterns, and Treatment Outcomes Before and After Humulin R U-500 Initiation and Device Switch Among Type 2 Diabetes Patients in the United... Yes Yes 32271 Finalised Not included in RMP Comparative Assessment of VTE and Other Risks among Patients with Rheumatoid Arthritis treated with Baricitinib versus Tumor Necrosis Factor... Yes Yes 32646 Planned EU RMP category 3 Dulaglutide and Potential Risks of Pancreatic Cancer and Thyroid Cancer: A Non-Interventional PASS (H9X-MC-B013) Yes No 32751 Planned Non-EU RMP-only A Registry-Based Observational Study to Assess Maternal, Pregnancy, and Infant Outcomes Following Exposure to Ixekizumab (I1F-MC-B010) Yes No 33068 Ongoing Not included in RMP preventive TReatment of mIgraine: oUtcoMes for Patients in real-world Healthcare systems [TRIUMPH] (15Q-MC-B004) No No 34204 Ongoing Not included in RMP Comparative assessment of venous thromboembolism and other risks among patients with rheumatoid arthritis treated with baricitinib versus tumor... No No 34213 Finalised Not included in RMP Post-Marketing Safety Study on Olumiant (Baricitinib) Use Among Moderate to Severe Active Rheumatoid Arthritis Patients in China Yes Yes 34966 Finalised Not included in RMP Effects of baricitinib on respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study... Yes Yes 36296 Ongoing Not included in RMP US Population-Based Longitudinal Survey in Migraine: ObserVational survey of the Epidemiology, tReatment and Care Of MigrainE (OVERCOME) Yes No 36306 Planned EU RMP category 3 An Observational Study to Assess the Utilisation and Safety of Ixekizumab Among Pediatric Patients Treated in the Course of Routine Clinical Care... Yes No 37093 Planned Not included in RMP EU Population-Based Cross-Sectional Survey in Migraine: ObserVational survey of the Epidemiology, tReatment and Care Of MigrainE (EU OVERCOME) No No 37245 Finalised Not included in RMP US-based cross-sectional survey in patients taking lasmiditan: Functional REstoration with rEyvow (FREE) Yes Yes 37841 Ongoing Not included in RMP A 24-Month Prospective Observational Cohort Study Evaluating Oral Systemic Therapies in the Management of Adult Patients with Atopic Dermatitis in... No No 39154 Finalised Not included in RMP Treatment Patterns, Treatment Outcomes, and Health Care Costs Before and After Humulin R U-500 Initiation or Device Change among Patients with Type 2... Yes Yes 39161 Finalised Not included in RMP Treatment Patterns, Treatment Outcomes, and Out-of-Pocket Pharmacy Costs Before and After Humulin R U-500 Initiation Among Type 2 Diabetes Patients in... Yes Yes 43239 Planned EU RMP category 3 Rheumatologist and Dermatologist Survey to Assess the Effectiveness of the Risk Minimisation Measures (RMM) for Olumiant (baricitinib), a JAK1/2... No No 44973 Ongoing Not included in RMP A prospective, registry based, observational study to asses maternal, fetal and infant outcomes following exposure to lasmiditan Yes No 44982 Ongoing Not included in RMP Observational cohort study of exposure to lasmiditan during pregnancy Yes No 45076 Ongoing EU RMP category 3 Medullary Thyroid Carcinoma Surveillance Study: a Case-Series Registry (H9X-MC-B001) Yes No 45172 Planned EU RMP category 3 Pancreatic Cancer and Thyroid Cancer Risks with Dulaglutide Treatment No No 47676 Planned Non-EU RMP-only A Prospective Post-Marketing Observational Safety Study of Cyramza® (Ramucirumab) in Patients with Gastric or Gastroesophageal Junction Adenocarcinoma... No No 49806 Planned Non-EU RMP-only Observational study of exposure to baricitinib during pregnancy in US-based administrative claims data (I4V-MC-B036) No No 49842 Planned Not included in RMP Characteristics and treatment patterns of patients with Obstructive Sleep Apnea (OSA) initiating Positive Airway Pressure (PAP) therapy No No 49988 Planned Not included in RMP Predicting Long-Term Outcome Risk with Tirzepatide: A Post-Hoc Analysis of SURMOUNT-1 Yes No 49999 Planned Not included in RMP Registry based observational study to assess pregnancy and infant outcomes following exposure to baricitinib in pregnancy (I4V-MC-B035) No No 50700 Planned Not included in RMP A Cohort Study to Evaluate the Real-World Utilization and Effectiveness of Bebtelovimab Compared to Paxlovid among Patients with Mild-to-Moderate... Yes No 103493 Ongoing Not included in RMP Weight regain after completion of SURMOUNT-CN trial: The SURMOUNT-CN trial follow-up study (SURMOUNT-CN follow-up study) No No 104191 Planned EU RMP category 3 Real-World Observational Study Using US Pharmacy Claims Data to Assess Safety Outcomes and Treatment Patterns in the US Among Migraine Patients... Yes No 104431 Planned EU RMP category 3 Baricitinib Drug Utilisation Study: Assessment of Effectiveness of New Recommendations for Use Based on Secondary Data Sources in France, Germany, The... No No 105321 Planned Not included in RMP A Prospective, Non-Interventional, Post-Marketing Observational Study Evaluating the Effectiveness and Safety of Selpercatinib Capsules in Adults and... Yes No 105671 Planned EU RMP category 3 Observational Secondary Database Study to Assess the Long-Term Safety of Mirikizumab (I6T-MC-B004) No No 105674 Planned EU RMP category 3 Observational Study of Pregnancy and Infant Outcomes Among Women Exposed to Mirikizumab During Pregnancy in US-based Administrative Claims Data... No No 107688 Planned Not included in RMP Mirikizumab Pregnancy Registry (I6T-MC-B006) No No 108949 Ongoing Not included in RMP The UK-Irish Atopic Eczema Systemic Therapy Register (A-STAR): Eli Lilly Engagement with A-STAR No No